A clinical study of latiglutenase as a treatment for type 1 diabetics with celiac disease
Ended Project Grant Awarded Last action
- Award ID
- R44DK121606
- Recipient
-
Immunogenx, Inc. UEI DHJSMHJ9BJE5
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,071,577
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Funding
-
- $3,138,005.00 Federal
- $933,572.00 Non-federal
- Place of performance
- Newport Beach, CA 92660, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $933,572 | $0 | |
| Amendment | $933,572 | $933,572 | |
| Amendment | $977,604 | $0 | |
| Original award | $293,257 | $0 |
Quick answers
Who received award R44DK121606?
R44DK121606 was awarded to Immunogenx, Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 8, 2020.
How much is award R44DK121606 worth?
$4,071,577 has been obligated on R44DK121606: $3,138,005 in federal funding and $933,572 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award